# Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977

> **NCT04862286** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 132 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT04862286
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-24
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862286, "Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04862286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*